Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

Klepzig, H; Kober, G.; Matter, Christian M; Luus, H. G.; Schneider, Hanan; Boedeker, K H; Kiowski, W; Amann, Franz W.; Gruber, Doris; Harris, Scott L.; Burger, Wolfram

doi:10.1053/euhj.1998.1242

Cited by 210 publications

(130 citation statements)

References 29 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Sulfonylurea-induced potassium efflux has been shown to reduce cardiac ischemic preconditioning in animal studies (9). In humans undergoing coronary angioplasty, the infusion of glimepiride has the same effect on ST depression and time to onset of angina as placebo, whereas the infusion of glyburide leads to a reduction in each of the effects of preconditioning (10).…”

mentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

et al. 2007

View full text Add to dashboard Cite

OBJECTIVE -Glyburide is the most widely used sulfonylurea but has unique pharmacodynamic properties that may increase harm. We hypothesized that glyburide causes more hypoglycemia and cardiovascular events than other secretagogues or insulin.RESEARCH DESIGN AND METHODS -Data sources were Medline, Embase, Cochrane, and three other web-based clinical trial registers (1966 -2005). Parallel, randomized, controlled trials in people with type 2 diabetes comparing glyburide monotherapy with monotherapy using secretagogues or insulin were selected. Outcomes were hypoglycemia, glycemic control, cardiovascular events, body weight, and death. Titles and abstracts of 1,806 publications were reviewed in duplicate and 21 relevant articles identified. Data on patient characteristics, interventions, outcomes, and validity were extracted in duplicate using predefined criteria. CONCLUSIONS -Glyburide caused more hypoglycemia than other secretagogues and other sulfonylureas. Glyburide was not associated with an increased risk of cardiovascular events, death, or weight gain. RESULTS Diabetes Care 30:389 -394, 2007T he global prevalence of diagnosed type 1 and 2 diabetes was estimated to be 2.8% in 2000 and projected to be 4.4% by 2030 (1). The UK Prospective Diabetes Study (UKPDS) showed that improving glycemic control reduced longterm microvascular complications (2). However, intensive therapy increases the risk for severe hypoglycemia, which is associated with mortality and morbidity (3,4).Sulfonylurea drugs bind the sulfonylurea receptor, an ATP-sensitive K ϩ channel, and inhibit potassium efflux, which facilitates insulin secretion (5). Compared with placebo, they reduce A1C levels by 1-2% (6). Differences in chemical structure, pharmacokinetic, and pharmacodynamic properties between sulfonylureas may lead to differences in the rates of hypoglycemic reactions. Glyburide (called glibenclamide in Europe), the most widely used sulfonylurea (7), has a relatively long terminal half-life in chronic dosing compared with other sulfonylureas, owing to its high affinity for the ␤-cell sulfonylurea receptor and the accumulation of active metabolites that are excreted through the kidney (7). Several observational studies have reported increased rates of hypoglycemia with the use of glyburide compared with other sulfonylureas (3,4). A systematic review of randomized controlled trials (RCTs) evaluating the risk for hypoglycemia associated with the use of glyburide has not, to our knowledge, been previously conducted.The University Group Diabetes Program (UGDP) RCT (8) noted excess cardiac deaths in patients treated with tolbutamide; whether this was attributable to higher baseline cardiac risk in the patients allocated to tolbutamide or to a true biological effect has been widely debated. Consistent with the findings of the UGDP study, experimental laboratory data have suggested that sulfonylureas, particularly glyburide, might increase the risk of cardiovascular events. During coronary angioplasty, with each subsequent balloon dilatation, t...

show abstract

mentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

et al. 2007

View full text Add to dashboard Cite

show abstract

“…There are also data providing indirect evidence that glibenclamide, but not glimepiride, prevents preconditioning in humans subjected to balloon angioplasty. 6 If glimepiride has fewer cardiac actions than other sulfonylureas, then this would have important implications for its preferred use in the treatment of patients with type 2 diabetes with concurrent coronary artery disease.…”

mentioning

confidence: 99%

Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide

et al. 2001

View full text Add to dashboard Cite

Background-The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial K ATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect nonpancreatic K ATP channels less than does Glib. We examined the effects of Glim on IP and on the protection afforded by diazoxide (Diaz), an opener of mitochondrial K ATP channels. Methods and Results-Rat hearts were Langendorff-perfused, subjected to 35 minutes of regional ischemia and 120 minutes of reperfusion, and assigned to 1 of the following treatment groups: (1) control; (2) IP of 2ϫ 5 minutes each of global ischemia before lethal ischemia; or pretreatment with (3) 30 mol/L Diaz, (4) 10 mol/L Glim, (5) 10 mol/L Glib, (6) IPϩGlim, (7)

show abstract

“…These lesions lead to hypertension, renal failure (nephropathy), blindness (retinopathy), autonomic and peripheral neuropathy, amputations of the lower extremities, myocardial infarction, and cerebrovascular accidents. (Lebovitz, 1997;Inzucchi, 2002;Bayraktar et al, 1996;Chiasson et al, 2002), biguanides to target hepatic insulin resistance (Bailey and Turner, 1996;Zhou et al, 2001;Holmes et al, 1999;, insulin secretagogues to increase pancreatic insulin secretion (Klepzig et al, 1999;Lebovitz, 2001;Hatorpe, 2002;, insulin sensitizers or thiazolidinediones which function as ligands for the peroxisome proliferator-activated receptor gamma (PPARγ) to target adipocyte and muscle insulin resistance (Lister et al, 1999;Finegood et al, 2001;Bell, 2003;Bakris et al, 2003;Herz et al, 2003;Nesto et al, 2003;Kelly et al, 1999;Lee et al, 2003), and intestinal lipase inhibitor or orlistat to inhibit fat absorption and promote weight loss in obese patients (Guerciolini, 1997;Hollander et al, 1998;Hanefeld and Sachse, 2002;Kelley et al, 2002).…”

Section: Chronic Complications Of Diabetesmentioning

confidence: 99%

Hypoglycemic Efficacy of Catharanthus roseus and Opuntia ficusindica in Mice Diabetic Model

Jaya¹,

Kumar²

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

Abstract: These results show that glimepiride maintains myocardial preconditioning, while glibenclamide might be able to prevent it.

Cited by 210 publications

References 29 publications

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide

Hypoglycemic Efficacy of Catharanthus roseus and Opuntia ficusindica in Mice Diabetic Model

Contact Info

Product

Resources

About